InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,634.00
(
0.79%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
87.10
(
0.75%
)
Bitcoin
59,867.73
(
-3.48%
)
Post# of 252474
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: biomaven0 post# 85494

Thursday, 10/29/2009 7:45:18 AM

Thursday, October 29, 2009 7:45:18 AM

Post# of 252474
On CNS side effects of VVUS drug, I've posted similar thoughts (http://siliconinvestor.advfn.com/readmsg.aspx?msgid=26052980). Safety profile looks approvable to me although the FDA will probably ask for a panel review as well as REMS program, especially since obesity drugs are expected to be overused. Other problems I see for VVUS are reimbursement (that goes for all obesity branded drugs), use of Qnexa's generic components, and possible IP issue with JNJ.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up